5464
Noha Hamdy Ahmad El-taweel
Studyng the expression of miRNA -186-3p and miRNA -96 in the beta thalassemic patients
MicroRNA, thalassemic ,HbF induction
Beta-thalassemia is one of the most common autosomal recessive disorders worldwide. The clinical severity of β-thalassemia is related to the extent of imbalance between the α-globin and non-alpha globin chains which include β and γ globin chains. Gamma globin chains are present in a small amount in normal adult individuals and in increased but variable amount in the β-thalassemia syndromes. Treatment of thalassemia is a major challenge especially in developing countries because of the financial burden it imposes still not curative nor providing the patients with adequate quality of life. Induction of HbF in β-Thalassemia patients is expected to be crucial for several developing countries unable to sustain the high cost of clinical management of β-Thalassemia. MicroRNAs are endogenous noncoding single-stranded RNAs of 19–25 nucleotides in length. They regulate gene expression and are important in a wide range of physiological and pathological processes. Moreover, miRNAs can be detected in a variety of sources, including tissue, blood and body fluids; they are reasonably stable and appear to be resistant to differences in sample handling, which increases their appeal as practical biomarkers. The clinical utility of miRNAs as diagnostic or prognostic biomarkers has been demonstrated in various malignancies and a few non-malignant diseases. Preliminary data suggest that miRNAs are promising as candidate biomarkers of diagnosis, prognosis, disease activity and severity in different diseases.
2018
M.Sc
Al-Azhar
Pharmacy